Ionis Pharmaceuticals IONS Proceeds From Sale Of Future Royalties
Proceeds From Sale Of Future Royalties at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:ProceedsFromSaleOfFutureRoyalties.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's proceeds from sale of future royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's proceeds from sale of future royalties?
- Ionis Pharmaceuticals (IONS) reported proceeds from sale of future royalties of $0 in Q4 2025.
- What is the long-term trend for Ionis Pharmaceuticals's proceeds from sale of future royalties?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's proceeds from sale of future royalties has grown at a -100.0% compound annual growth rate (CAGR), from $500M to $0.
- What does proceeds from sale of future royalties mean?
- Cash received today by selling the rights to future royalty income.
- How do you interpret proceeds from sale of future royalties?
- High proceeds indicate a successful monetization of intellectual property, providing immediate liquidity at the cost of future revenue.
- How does proceeds from sale of future royalties compare across companies?
- Common in pharmaceutical and biotech firms with established commercialized products.